Myriad Genetics
MYGN
MYGN
197 hedge funds and large institutions have $2.25B invested in Myriad Genetics in 2021 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 53 increasing their positions, 73 reducing their positions, and 25 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
197
Holders Change
+10
Holders Change %
+5.35%
% of All Funds
3.47%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
%
% of All Funds
0.04%
New
36
Increased
53
Reduced
73
Closed
25
Calls
$5.65M
Puts
$2.59M
Net Calls
+$3.06M
Net Calls Change
+$1.62M
Top Buyers
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
$82.8M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
$26.8M |
| 3 |
BlackRock
New York
|
$403M |
| 4 |
Invesco
Atlanta,
Georgia
|
$29.9M |
| 5 |
EARNEST Partners
Atlanta,
Georgia
|
$219M |
Top Sellers
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
$91.4M |
| 2 |
Morgan Stanley
New York
|
$22.7M |
| 3 |
GCM
Glenview Capital Management
New York
|
$78.2M |
| 4 |
D.E. Shaw & Co
New York
|
$81M |
| 5 |
Northern Trust
Chicago,
Illinois
|
$38.5M |
